Importantly, you must be logged into Zoom using the company email address to be authenticated to view the
townhall. Please be prepared to keep your camera turned on for the duration of the session.
This is an important next step in NantKwests long-term
strategy and I hope you are as excited as I am for the opportunity we are creating. This combination builds on our collaborative legacy and I am confident that we will reach even greater heights as one team.
I would like to thank all of you for your continued dedication to our mission and for all you do to push the boundaries of science and provide new options for
our patients. I am wishing you and your families a happy holiday and healthy New Year.
If you have any questions, please contact your manager
directly.
Gratefully,
Rich
Forward-Looking Statements
This communication contains
forward-looking statements relating to the proposed transaction involving NantKwest, Inc. (NantKwest) and ImmunityBio, Inc. (ImmunityBio), including financial estimates and statements as to the expected timing, completion and
effects of the proposed transaction and statements relating to NantKwest and ImmunityBios future success in improving the treatment of various diseases and illnesses, including, but not limited to
COVID-19 and cancer. Statements in this communication that are not statements of historical fact are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as anticipates,
believes, continues, could, estimates, expects, intends, may, plans, potential, predicts, projects,
seeks, should, will, and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of NantKwests
management and ImmunityBios management as well as assumptions made by and information currently available to NantKwest and ImmunityBio. Such statements reflect the current views of NantKwest and ImmunityBio with respect to future events and
are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about NantKwest and ImmunityBio, including, without limitation, (i) inability to complete the
proposed transaction because, among other reasons, conditions to the closing of the proposed transaction may not be satisfied or waived, (ii) uncertainty as to the timing of completion of the proposed transaction, (iii) potential adverse
effects or changes to relationships with employees, suppliers or other parties resulting from the announcement or completion of the proposed transaction, (iv) the outcome of any legal proceedings that may be instituted against the parties and
others related to the merger agreement, (v) possible disruptions from the proposed transaction that could harm NantKwests or ImmunityBios respective business, including current plans and operations, (vi) unexpected costs,
charges or expenses resulting from the proposed transaction, (vii) uncertainty of the expected financial performance of the combined company following completion of the proposed transaction, including the possibility that the expected synergies
and value creation from the proposed transaction will not be realized or will not be realized within the expected time period, (viii) the ability of each of NantKwest or ImmunityBio to continue its planned preclinical and clinical development
of its respective development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (ix) inability to retain and hire key personnel, and (x) the unknown future
impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or NantKwests or ImmunityBios operations or operating expenses. More details about these and other risks that may
impact our business are described under the heading Risk Factors in NantKwests most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K
filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by NantKwest with the SEC, which are available on the SECs website at www.sec.gov. NantKwest and ImmunityBio caution you not to place undue
reliance on any forward-looking statements, which speak only as of the date hereof. NantKwest and ImmunityBio do not undertake any duty to update any forward-looking statement or other information in this communication, except to the extent required
by law. No representation is made as to the safety or effectiveness of these product candidates for the therapeutic use for which such product candidates are being studied.